Richard J. Buchholz

Chief Commercial Officer

Therapeutic Areas

Drug	Indication	Phase
Inspire 4.0 / Next-Gen System	Obstructive Sleep Apnea (OSA)	Development
Pediatric Indication (Down Syndrome)	OSA in Pediatric Patients with Down Syndrome	FDA Approved
Expanded AHI Range & Comorbidities	Broader OSA Patient Populations	Clinical Research
Apnea-Hypopnea Index (AHI) <15	Mild OSA	Exploratory
Therapy Optimization & AI	OSA Treatment Optimization	Research